GlaxoSmithKline reached a $105 million settlement with Georgia and 44 other states this week for misrepresenting uses and qualities of its drugs Advair, Paxil and Wellbutrin.
Georgia will get $2.62 million from the settlement, said John Sours, the administrator of the Governor’s Office of Consumer Protection. The money goes in the state’s general fund. The Office of Consumer Protection is charged with prosecuting violations of the Fair Business Practices Act.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
